Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Companies to Benefit from R&D Tax Break Reform
January 7, 2008
- TOPICS／NBI Helps Employees Manage Work and Family Life
January 7, 2008
- REGULATORY NEWS IN BRIEF
January 7, 2008
- Patient-Centered Healthcare - 10 Concerns of Patients
January 7, 2008
- 54 New Drugs Approved in 1st Half of FY2007: PMDA
January 7, 2008
- AstraZeneca to Start PI for 20 Products in 2008, as in 2007: CEO D. Brennan
January 7, 2008
- 7 New Products Included in NHI Price List
January 7, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 7, 2008
- NHI Drug Prices to Receive 5.2% Cut in April 2008
January 7, 2008
- Concurrent Use of Unapproved Drugs with Insurance-Covered Healthcare to Be Allowed
January 7, 2008
- Mean Gap of 6.9% Found between Market Prices and NHI Prices
January 7, 2008
- Banyu Commemorates 1st Anniversary of Preminent Launching
January 7, 2008
- Korosho, MOF Agree on 0.38% Increase in Medical Fees
January 7, 2008
- GENERICS NEWS IN BRIEF
January 7, 2008
- Gov't Decides to Increase Medical Fees 0.38%
January 7, 2008
- Kyowa Pharm. Ind. to Launch 20 New Products Every Year
January 7, 2008
- BUSINESS NEWS IN BRIEF
January 7, 2008
- SSP Revises Business Forecast Upward
January 7, 2008
- NEW PRODUCTS
January 7, 2008
- Taisho to Launch RiUP Plus
January 7, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…